Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CaPVax
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
CaPVax is an autologous dendritic cell-based cancer vaccine developed by the Jonsson Comprehensive Cancer Center (UCLA) for the treatment of metastatic hormone-refractory prostate cancer. The therapeutic process involves isolating a patient's peripheral blood mononuclear cells, which are then differentiated into mature dendritic cells ex vivo. These dendritic cells are loaded with recombinant prostate-specific membrane antigen (rPSMA), a protein highly expressed on the surface of prostate cancer cells. When re-infused into the patient, these antigen-presenting cells are designed to stimulate a robust, targeted T-cell immune response against PSMA-expressing tumor cells, potentially overcoming the immune tolerance often seen in advanced prostate cancer.
- Other names
- rPSMA-loaded autologous dendritic cell vaccinerPSMA-loaded mature autologous dendritic cellsRecombinant Prostate Specific Membrane Antigen-Loaded Mature Autologous Dendritic Cells
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on CaPVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CaPVax.